References
- Zain R, Vihinen M. Structure-function relationships of covalent and non-covalent BTK inhibitors. Front Immunol. 2021;12:694853.
- Vetrie D, Vorechovský I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361(6409):226–233. DOI:https://doi.org/10.1038/361226a0.
- de Weers M, Verschuren M, Kraakman M, et al. The Bruton’s tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. Eur J Immunol. 1993 [1993 Dec];23(12). Doi:https://doi.org/10.1002/eji.1830231210.
- Smith C, Islam T, Mattsson P, et al. The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. BioEssays. 2001;23(5):436–446. DOI:https://doi.org/10.1002/bies.1062.
- Estupiñán H, Berglöf A, Zain R, et al. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021 [Mar/11/2021];9. https://doi.org/10.3389/fcell.2021.630942.
- Rawlings D, Scharenberg A, Park H, et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science. 1996;271(5250):822–825. DOI:https://doi.org/10.1126/science.271.5250.822.
- Crofford L, Nyhoff L, Sheehan J, et al. The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy. Expert Rev Clin Immunol. 2016;12(7):763–773. DOI:https://doi.org/10.1586/1744666X.2016.1152888.
- Wen T, Wang J, Shi Y, et al. Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances. Leukemia. 2021;35(2):312–332. DOI:https://doi.org/10.1038/s41375-020-01072-6.
- Jongstra-Bilen J, Puig Cano A, Hasija M, et al. Dual functions of Bruton’s tyrosine kinase and tec kinase during fcgamma receptor-induced signaling and phagocytosis. J Iimmunol. 2008;181(1):288–298. DOI:https://doi.org/10.4049/jimmunol.181.1.288.
- Kawakami Y, Yao L, Miura T, et al. Tyrosine phosphorylation and activation of Bruton tyrosine kinase upon Fc epsilon RI cross-linking. Mol Cell Biol. 1994;14(8):5108–5113. DOI:https://doi.org/10.1128/mcb.14.8.5108-5113.1994.
- Saffran D, Parolini O, Fitch-Hilgenberg M, et al. Brief report: a point mutation in the SH2 domain of Bruton’s tyrosine kinase in atypical X-linked agammaglobulinemia. N Engl J Med. 1994;330(21):1488–1491. DOI:https://doi.org/10.1056/NEJM199405263302104.
- Davis R, Ngo V, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88–92. DOI:https://doi.org/10.1038/nature08638.
- Treon S, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012;367(9):826–833. DOI:https://doi.org/10.1056/NEJMoa1200710.
- Taurog J, Moutsopoulos H, Rosenberg Y, et al. CBA/N X-linked B-cell defect prevents NZB B-cell hyperactivity in F1 mice. J Exp Med. 1979;150(1):31–43. DOI:https://doi.org/10.1084/jem.150.1.31.
- Allen J, Tata P, Fore M, et al. Increased BCR responsiveness in B cells from patients with chronic GVHD. Blood. 2014;123(13):2108–2115. DOI:https://doi.org/10.1182/blood-2013-10-533562.
- Woyach J, Ruppert A, Heerema N, et al. Ibrutinib Regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528. DOI:https://doi.org/10.1056/NEJMoa1812836.
- Burger J, Tedeschi A, Barr P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437. DOI:https://doi.org/10.1056/NEJMoa1509388.
- Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med. 2015 Apr 9;372(15):1430–1440.
- Treon S, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naïve patients with waldenström macroglobulinemia. J clin oncol. 2018;36(27):2755–2761. DOI:https://doi.org/10.1200/JCO.2018.78.6426.
- Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013 Aug 8 369(6):507–516. https://doi.org/10.1056/NEJMoa1306220
- Lynch RC, Advani RH. Dramatic response with single-agent ibrutinib in multiply relapsed marginal zone lymphoma with MYD88(L265P) mutation. Case Rep Oncol. 2017 Sep-Dec;10(3):813–818.
- Pharmacyclics LLC, Janssen Biotech II (Imbruvica). 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210563s000lbl.pdf. [Accessed November 01, 2021].
- Awan FT, Al-Sawaf O, Fischer K, et al. Current perspectives on therapy for chronic lymphocytic leukemia. Am Soc Clin Oncol Educ Book. 2020 Mar;40:1–10. https://doi.org/10.1200/EDBK_279099
- AstraZeneca. Acalabrutinib (Calquence) 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf .[Accessed November 01, 2021].
- Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019 May 14;3(9):1553–1562. https://doi.org/10.1182/bloodadvances.2018030007.
- Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28 374(4):323–332. https://doi.org/10.1056/NEJMoa1509981
- Owen RG, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol. 2020;7(2):e112–e121. DOI:https://doi.org/10.1016/S2352-3026(19)30210-8.
- Sharman J, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–1291. DOI:https://doi.org/10.1016/S0140-6736(20)30262-2.
- An G, Zhou D, Cheng S, et al. A phase ii trial of the bruton tyrosine-kinase inhibitor zanubrutinib (BGB-3111) in patients with relapsed/refractory waldenström macroglobulinemia. Clin Cancer Res. 2021. DOI:https://doi.org/10.1158/1078-0432.CCR-21-0539.
- Song Y, Zhou K, Zou D, et al. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of bruton’s tyrosine kinase. Clin Cancer Res. 2020;26(16). DOI:https://doi.org/10.1158/1078-0432.CCR-19-3703.
- Tam C, Opat S, D’Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038–2050. DOI:https://doi.org/10.1182/blood.2020006844.
- Beigene. Zanubrutinib (Brukinsa) 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf .[Accessed November 01, 2021].
- Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematol Am Soc Hematol Educ Program. 2020;2020(1):336–345.
- Dickerson T, Wiczer T, Waller A, et al., Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 134(22): 1919–1928. 2019. https://doi.org/10.1182/blood.2019000840.
- Guha A, Derbala M, Zhao Q, et al. Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies. J Am Coll Cardiol. 2018;72(6):697–698. DOI:https://doi.org/10.1016/j.jacc.2018.06.002.
- Wiczer T, Levine L, Brumbaugh J, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017;1(20):1739–1748. DOI:https://doi.org/10.1182/bloodadvances.2017009720.
- Khountham S, Shindiapina P, Mo X, et al. Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2021;62(3):716–721. DOI:https://doi.org/10.1080/10428194.2020.1838508.
- Mato A, Nabhan C, Thompson M, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874–879.
- Mato A, Nabhan C, Barr P, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016;128(18):2199–2205. DOI:https://doi.org/10.1182/blood-2016-05-716977.
- Byrd J, Brown J, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223. DOI:https://doi.org/10.1056/NEJMoa1400376.
- RR F, JC B, RG O, et al. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia. 2021;35(11):3201–3211. Doi:https://doi.org/10.1038/s41375-021-01252-y.
- Ruppert A, Booth A, Ding W, et al. Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: alliance A041202. Leukemia. 2021. DOI:https://doi.org/10.1038/s41375-021-01342-x.
- Chen J, Kinoshita T, Sukbuntherng J, et al. Ibrutinib inhibits ERBB receptor tyrosine kinases and HER2-amplified breast cancer cell growth. Mol Cancer Ther. 2016 [2016 Dec];15(12):2835–2844. DOI:https://doi.org/10.1158/1535-7163.MCT-15-0923.
- Dubovsky J, Beckwith K, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539–2549. DOI:https://doi.org/10.1182/blood-2013-06-507947.
- Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107(29):13075–13080. DOI:https://doi.org/10.1073/pnas.1004594107.
- Caldeira D, Alves D, Costa J, et al. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PloS one. 2019 [Feb/20/2019];14(2):e0211228. DOI:https://doi.org/10.1371/journal.pone.0211228.
- Byrd J, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III Trial. J clin oncol. 2021;39(31):3441–3452. DOI:https://doi.org/10.1200/JCO.21.01210.
- Fradley M, Gliksman M, Emole J, et al. Rates and risk of atrial arrhythmias in patients treated with ibrutinib compared with cytotoxic chemotherapy. Am J Cardiol. 2019;124(4):539–544. DOI:https://doi.org/10.1016/j.amjcard.2019.05.029.
- Shanafelt T, Parikh S, Noseworthy P, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017;58(7):1630–1639. DOI:https://doi.org/10.1080/10428194.2016.1257795.
- Thompson P, Lévy V, Tam C, et al. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol. 2016;175(3):462–466. DOI:https://doi.org/10.1111/bjh.14324.
- Gustine J, Meid K, Dubeau T, et al. Atrial fibrillation associated with ibrutinib in waldenström macroglobulinemia. Am J Hematol. 2016;91(6):E312–E313. DOI:https://doi.org/10.1002/ajh.24366.
- Lee H, Chihara D, Wang M, et al. Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma. Leuk Lymphoma. 2016;57(12):2914–2916. DOI:https://doi.org/10.3109/10428194.2016.1169408.
- Thorp B, Badoux X. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management. Leuk Lymphoma. 2018;59(2):311–320.
- Xiao L, Salem J, Clauss S, et al. Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal src kinase. Circulation. 2020;142(25):2443–2455.
- Awan F, Tong D, Zaha V. Cardio-Oncology: a win-win situation: how solving the mystery of an ibrutinib off-target effect reveals new insights into atrial fibrillation mechanisms. Circulation. 2020;142(25):2456–2458.
- Jiang L, Li, L L, et al. Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium. Heart Rhythm. 2019;16(9):1374–1382. DOI:https://doi.org/10.1016/j.hrthm.2019.04.008.
- Molica S, Lentini M, Zappala D, et al. Effects of ibrutinib on glucose-lipid metabolism in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2020 Nov;61(11):2778–2780. DOI:https://doi.org/10.1080/10428194.2020.1779258.
- Bye A, Unsworth A, Vaiyapuri S, et al. Ibrutinib inhibits platelet integrin α IIb β 3 outside-in signaling and thrombus stability but not adhesion to collagen. Arterioscler Thromb Vasc Biol. 2015;35(11):2326–2335. DOI:https://doi.org/10.1161/ATVBAHA.115.306130.
- Dobie G, Kuriri F, Omar M, et al. Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans. Blood Adv. 2019;3(24):4298–4311. DOI:https://doi.org/10.1182/bloodadvances.2019000640.
- Lipsky A, Farooqui M, Tian X, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015;100(12):1571–1578. DOI:https://doi.org/10.3324/haematol.2015.126672.
- Byrd J, Furman R, Coutre S, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42. DOI:https://doi.org/10.1056/NEJMoa1215637.
- Gage B, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110(16):2287–2292. DOI:https://doi.org/10.1161/01.CIR.0000145172.55640.93.
- Pisters R, Lane D, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100. DOI:https://doi.org/10.1378/chest.10-0134.
- Brown J, Moslehi J, Ewer M, et al. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis. Br J Haematol. 2019;184(4):558–569. DOI:https://doi.org/10.1111/bjh.15690.
- Dmitrieva E, Nikitin E, Ignatova A, et al. Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib. J Thromb Haemost. 2020;18(10):2672–2684. DOI:https://doi.org/10.1111/jth.14943.
- Ruff C, Giugliano R, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. DOI:https://doi.org/10.1016/S0140-6736(13)62343-0.
- Byrd J, Furman R, Coutre S, et al. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC-1102 Study. Clin Cancer Res. 2020;26(15):3918–3927.
- Ahn I. Cardiovascular adverse events of ibrutinib.Blood. 2019 [Nov/28/2019];134(22):1881–1882. DOI:https://doi.org/10.1182/blood.2019002805.
- Ping L, Ding N, Shi Y, et al. The Bruton’s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. Oncotarget. 2017;8(24). DOI:https://doi.org/10.18632/oncotarget.16836.
- Pandey A, Singhi E, Arroyo J, et al. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease. Hypertension. 2018;71(2). DOI:https://doi.org/10.1161/HYPERTENSIONAHA.117.10271.
- Liu N, Rowley B, Bull C, et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. Mol Cancer Ther. 2013;12(11):2319–2330. DOI:https://doi.org/10.1158/1535-7163.MCT-12-0993-T.
- McMullen J, Boey E, Ooi J, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829–3830. DOI:https://doi.org/10.1182/blood-2014-10-604272.
- Whelton P, Carey R, Aronow W, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/apha/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Hypertension. 2018;71(6):1269–1324. Doi:https://doi.org/10.1161/HYP.0000000000000066.
- Unger T, Borghi C, Charchar F, et al. International Society of Hypertension global hypertension practice guidelines. J Hypertens. 2020;38(6):982–1004. 2020. DOI:https://doi.org/10.1097/HJH.0000000000002453.
- Williamson J, Williamson J, Whelton P, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–2116. DOI:https://doi.org/10.1056/NEJMoa1511939.
- Lewis C, Fine L, Beddhu S, et al. Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med. 2021;384(20):1921–1930. DOI:https://doi.org/10.1056/NEJMoa1901281.
- Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016 [2016 Feb];17(2):200–211. DOI:https://doi.org/10.1016/S1470-2045(15)00465-9.
- Lampson B, Yu L, Glynn R, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017;129(18):2581–2584. DOI:https://doi.org/10.1182/blood-2016-10-742437.
- Winqvist M, Asklid A, Andersson P, et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish chronic lymphocytic leukemia group. Haematologica. 2016;101(12):1573–1580. DOI:https://doi.org/10.3324/haematol.2016.144576.
- Farooqui M, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16(2):169–176. DOI:https://doi.org/10.1016/S1470-2045(14)71182-9.
- Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062–2067. DOI:https://doi.org/10.1182/blood-2014-09-603670.
- Maddocks K, Ruppert A, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1(1):80. DOI:https://doi.org/10.1001/jamaoncol.2014.218.
- Kudinov A, Darbar D. Deciphering the electrophysiological mechanisms for ibrutinib-induced ventricular arrhythmias. JACC CardioOncology. 2020 [Nov/17/2020];2(4):630–631. Doi:https://doi.org/10.1016/j.jaccao.2020.10.001.
- Du B, Chakraborty P, Azam M, et al. Acute effects of ibrutinib on ventricular arrhythmia in spontaneously hypertensive rats. JACC CardioOncology. 2020 Nov/17/2020;2(4):614–629. https://doi.org/10.1016/j.jaccao.2020.08.012.
- Abdel-Qadir H, Sabrie N, Leong D, et al. Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: a population-based cohort study. J Clin Oncol. 2021 Nov 1 39(31):3453–3462. https://doi.org/10.1200/JCO.21.00693
- Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9. DOI:https://doi.org/10.1186/s13045-016-0250-9
- Brown MP JR, Byrd M JC, Paolo Ghia MP, et al. Pooled analysis of cardiovascular events from clinical trials evaluating acalabrutinib monotherapy in patients with chronic lymphocytic leukemia. Blood. 2020;136:52–54.
- Furman R, Byrd J, Owen R, et al. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia. 2021;35:3201–3211.
- Bye A, Unsworth A, Desborough M, et al. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Adv. 2017;1(26):2610–2623. DOI:https://doi.org/10.1182/bloodadvances.2017011999.
- Tang C, McMullen J, Tam C. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. Leuk Lymphoma. 2020;38(25):2849–2861. Doi:https://doi.org/10.1200/JCO.19.03355.
- Ghia P, Pluta A, Wach M, et al. ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020 [Sep/01/2020];38(25):2849–2861. DOI:https://doi.org/10.1200/JCO.19.03355.
- Bond D, Woyach J. Targeting BTK in CLL: beyond Ibrutinib. Curr Hematol Malig Rep. 2019;14(3):197–205.
- Hillmen P, Eichorst B, Brown J, et al. editors. First interim analysis of alpine study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. European Hematology Association. 2021;330170:LB1900.
- Brown J, Robak T, Ghia P, et al. editors. Efficacy and safety of zanubrutinib in patients with treatment-naïve (tn) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): Follow-up results from arm C of the SEQUOIA (BGB-3111-304) trial. Blood. 2020;136(Supplement 1): 11–12
- Tam C, Opat S, Simpson D, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021;5(12):2577–2585. DOI:https://doi.org/10.1182/bloodadvances.2020004074.
- Tam C, Quach H, Nicol A, et al. Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. Blood Adv. 2020;4(19):4802–4811. DOI:https://doi.org/10.1182/bloodadvances.2020002183.
- Munakata W, Ando K, Hatake K, et al. Phase I study of tirabrutinib (ONO 4059/GS 4059) in patients with relapsed or refractory B-cell malignancies in Japan. Cancer Sci. 2019;110(5):1686–1694. DOI:https://doi.org/10.1111/cas.13983.
- Narita Y, Nagane M, Mishima K, et al. Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol. 2021;23(1):122–133. DOI:https://doi.org/10.1093/neuonc/noaa145.
- Sekiguchi N, Rai S, Munakata W, et al. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström’s macroglobulinemia. Cancer Sci. 2020;111(9):3327–3337. DOI:https://doi.org/10.1111/cas.14561.
- Walter H, Jayne S, Rule S, et al. Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059. Blood. 2017;129(20):2808–2810. DOI:https://doi.org/10.1182/blood-2017-02-765115.
- Romero D. Initial pirtobrutinib data show promise. Nat Rev Clin Oncol. 2021;18(5):258.
- Mato A, Shah N, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892–901. DOI:https://doi.org/10.1016/S0140-6736(21)00224-5.
- Crawford J, Johnson A, Misner D, et al. Discovery of GDC-0853: a potent, selective, and noncovalent bruton’s tyrosine kinase inhibitor in early clinical development. J Med Chem. 2018;61(6):2227–2245. DOI:https://doi.org/10.1021/acs.jmedchem.7b01712.
- Cohen S, Tuckwell K, Katsumoto T, et al. Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase ii trial (andes study). Arthritis Rheumatol. 2020;72(9). DOI:https://doi.org/10.1002/art.41275.
- Byrd JC, Wierda WG, Schuh A, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020 Apr 9 135(15):1204–1213. https://doi.org/10.1182/blood.2018884940